| Back |
|
| A willful support |
| Product Name: |
| Injections |
| Ceftazidime 125/250/500/1000 mg |
|
| Offers favourable pharmacokinetic profile - Longer plasma half-life (114-120 min.), Effect of full dose is observed, From 80% to 90% is excreted unchanged in the urine |
| Useful as empirical treatment in febrile neutropenic patients |
| Helpful as an adjunct of aminoglycosides, vancomycin, and clindamycin in severe and life-threatning infections and in the immunocompromised patients |
|
| "Ceftazidime's time-dependent pharmacokinetics shows the advantage of continous infusion. This study confirmed the feasibility and safety of this administration schedule in the empirical treatment of febrile neutropenic children with cancer."
|
|
| Indications:
|
| Lower respiratory tract infections
|
| Skin and Skin structure infections
|
| Complicated and uncomplicated urinary tract infections
|
| Bone and joint infections
|
| Gynaecological infections
|
| CNS infections
|
|
Medical Jr.
| Dalle JH et al. J Pediatr Hematol Oncol. 2002 Dec;24(9): 714-6
|
|
| |
|
 |